{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:21:40Z","timestamp":1782822100609,"version":"3.54.5"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Heart failure (HF) following acute myocardial infarction (AMI) significantly impacts morbidity and mortality. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed for type 2 diabetes mellitus, have shown cardiovascular benefits. This study evaluates the efficacy of SGLT2 inhibitors in treating HF post-AMI compared to conventional treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study at our hospital from September 2022 to September 2024 involving 315 patients with HF post-AMI. Patients were categorized into a conventional treatment group (n = 140) and an SGLT2 inhibitor group (n = 175), with the latter further divided into effective (n = 154) and ineffective (n = 21) subgroups. Cardiac function was assessed pre- and post-treatment using echocardiography and serum biomarkers. Baseline characteristics and potential predictors of SGLT2 efficacy were also analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The SGLT2 group exhibited significant improvements in left ventricular ejection fraction (LVEF), decreased NT-proBNP, troponin I, and hs-CRP levels compared to the conventional group (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). The overall effectiveness rate was 88.00% versus 75.71% in the conventional group (\n                      <jats:italic>P =<\/jats:italic>\n                      0.004). Lower baseline LVEF and higher NT-proBNP levels were significant predictors of better outcomes. Notably, adverse reactions such as angina were reduced in the SGLT2 group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2 inhibitors were associated with enhanced cardiac function and reduce cardiac stress markers in HF patients post-AMI, suggesting their potential as an adjunctive therapy. Lower baseline LVEF and higher NT-proBNP levels may predict better response, suggesting their utility in personalized treatment strategies. This was a retrospective single-center study, and further prospective trials are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1693420","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:22:49Z","timestamp":1761805369000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and influencing factors analysis of SGLT2 inhibitors in treating heart failure following acute myocardial infarction"],"prefix":"10.3389","volume":"16","author":[{"given":"Haiping","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwei","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/ehjcvp\/pvab056","article-title":"Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence","volume":"8","author":"Aguilar-Gallardo","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pcad.2024.01.017","article-title":"The spectrum of post-myocardial infarction care: from acute ischemia to heart failure","volume":"82","author":"Akhtar","year":"2024","journal-title":"Prog. Cardiovasc. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12933-024-02154-w","article-title":"The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis","volume":"23","author":"Ali","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1002\/ehf2.14510","article-title":"Differences between cardiogenic shock related to acute decompensated heart failure and acute myocardial infarction","volume":"10","author":"Bertaina","year":"2023","journal-title":"Esc. Heart Fail"},{"key":"B5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/heartjnl-2022-320808","article-title":"Man with recent myocardial infarction and heart failure","volume":"108","author":"Bhasin","year":"2022","journal-title":"Heart"},{"key":"B6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10557-020-06973-3","article-title":"Sodium-glucose Co-transporter 2 inhibitors in the failing heart: a growing potential","volume":"34","author":"Brito","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/ehjcvp\/pvaf026","article-title":"SGLT2 inhibitors and cardiovascular outcomes in patients with acute myocardial infarction: a retrospective cohort analysis","volume":"11","author":"Ci Mee","year":"2025","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2459\/JCM.0000000000001409","article-title":"Updates in heart failure: sodium glucose co-transporter 2 inhibitors and beyond - major changes are coming","volume":"23","author":"Cimino","year":"2022","journal-title":"J. Cardiovasc. Med. Hagerst."},{"key":"B9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-023-01743-5","article-title":"The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (\u226575 years): a retrospective, pharmacovigilance study","volume":"22","author":"Goldman","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"102193","DOI":"10.1016\/j.cpcardiol.2023.102193","article-title":"Application of eligibility criteria from DAPA-HF, EMPEROR-Reduced, and PARADIGM-HF trials to a population with heart failure with reduced ejection fraction at a specialized cardiology clinic in medellin, Colombia: a retrospective cohort study","volume":"49","author":"Gonzalez-Franco","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-021-01316-4","article-title":"Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis","volume":"20","author":"Hinton","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12933-023-01822-7","article-title":"Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review","volume":"22","author":"Hoehlschen","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10557-021-07249-0","article-title":"Sodium-glucose Co-transporter 2 inhibitors Versus metformin as the first-line treatment for type 2 diabetes: is it time for a revolution?","volume":"37","author":"Koufakis","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/XCE.0000000000000209","article-title":"Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond","volume":"10","author":"Lahoti","year":"2021","journal-title":"Cardiovasc. Endocrinol. Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12933-022-01526-4","article-title":"Sodium-glucose co-transporter-2 inhibitors in the treatment of diabetes with heart failure","volume":"21","author":"Liang","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12872-022-02693-8","article-title":"Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction","volume":"22","author":"Liang","year":"2022","journal-title":"BMC Cardiovasc. Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12265-022-10302-4","article-title":"Empagliflozin for patients with heart failure and type 2 diabetes mellitus: clinical evidence in comparison with other sodium-glucose Co-transporter-2 inhibitors and potential mechanism","volume":"16","author":"Liang","year":"2023","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"966708","DOI":"10.3389\/fcvm.2022.966708","article-title":"Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: a population-based cohort study","volume":"9","author":"Lin","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.31083\/j.rcm2303082","article-title":"The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys","volume":"23","author":"Lioudaki","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1010693","DOI":"10.3389\/fcvm.2022.1010693","article-title":"Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary","volume":"9","author":"Mascolo","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.31083\/j.rcm2304139","article-title":"Sodium-glucose Co-transporter 2 inhibitors in acute heart failure: a review of the available evidence and practical guidance on clinical use","volume":"23","author":"Morillas","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/ehjcvp\/pvad088","article-title":"Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Oriecuia","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jchf.2024.02.020","article-title":"Contemporary American and european Guidelines for heart failure management: JACC: heart failure guideline comparison","volume":"12","author":"Ostrominski","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e12970","DOI":"10.1111\/sji.12970","article-title":"An inflammation classification system using cytokine parameters","volume":"93","author":"Roe","year":"2021","journal-title":"Scand. J. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cnur.2015.07.012","article-title":"Heart failure: pathophysiology, diagnosis, medical treatment guidelines, and nursing management","volume":"50","author":"Rogers","year":"2015","journal-title":"Nurs. Clin. North Am."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1093\/ehjcvp\/pvab012","article-title":"Sodium-glucose co-transporter 2 inhibitors in heart failure","volume":"7","author":"Rosano","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.numecd.2020.05.030","article-title":"Sodium-glucose co-transporter-2 inhibitors: peculiar \u201chybrid\u201d diuretics that protect from target organ damage and cardiovascular events","volume":"30","author":"Sarzani","year":"2020","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12933-023-01897-2","article-title":"The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study","volume":"22","author":"Werkman","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"30148","DOI":"10.1038\/s41598-024-81954-2","article-title":"Effect of sodium glucose cotransporter 2 inhibitors on all cause death and rehospitalization for heart failure in patients with acute myocardial infarction","volume":"14","author":"Xiong","year":"2024","journal-title":"Sci. Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12933-025-02777-7","article-title":"Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review","volume":"24","author":"Yoo","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"768214","DOI":"10.3389\/fcvm.2021.768214","article-title":"Sodium-glucose Co-transporter-2 inhibitor of dapagliflozin attenuates myocardial ischemia\/reperfusion injury by limiting NLRP3 inflammasome activation and modulating autophagy","volume":"8","author":"Yu","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12933-019-0984-0","article-title":"Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?","volume":"19","author":"Yurista","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"636152","DOI":"10.3389\/fcvm.2021.636152","article-title":"Mechanisms and perspectives of sodium-glucose Co-transporter 2 inhibitors in heart failure","volume":"8","author":"Zeng","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/2048872619894254","article-title":"Acute cardiovascular care association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: a document of the acute cardiovascular care association of the european society of cardiology","volume":"9","author":"Zeymer","year":"2020","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1693420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:22:49Z","timestamp":1761805369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1693420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":34,"alternative-id":["10.3389\/fphar.2025.1693420"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1693420","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"article-number":"1693420"}}